- 作者: Szu-Chia Lai; Pele Choi-Sing Chong; Chia-Tsui Yeh; Levent Shih-Jen Liu; Jia-Tsrong Jan; Hsiang-Yun Chi; Hwan-Wun Liu; Ann Chen; Yeau-Ching Wang
- 作者服務機構: 1 Institute of Preventive Medicine, National Defense Medical Center, 90048-700, San-Hsia, Taipei, Taiwan;; 2 Vaccine Research and Development Center, National Health Research Institutes, Taiwan
- 中文摘要: --
- 英文摘要: The spike (S) glycoprotein is thought to play a complex and central role in the biology and pathogenesis of SARS coronavirus infection. In this study, a recombinant protein (rS268, corresponding to residues 268-1255 of SARS-CoV S protein) was expressed in Escherichia coli and was purified to near homogeneity. After immunization with rS268, S protein-specific BALB/c antisera and mAbs were induced and confirmed using ELISA, Western blot and IFA. Several BALB/c mAbs were found to be effectively to neutralize the infection of Vero E6 cells by SARS-CoV in a dose-dependent manner. Systematic epitope mapping showed that all these neutralizing mAbs recognized a 15-residues peptide (CB-119) corresponding to residues 1143— 1157 (SPDVDLGDISGINAS) that was located to the second heptad repeat (HR2) region of the SARS-CoV spike protein. The peptide CB-119 could specifically inhibit the interaction of neutralizing mAbs and spike protein in a dose-dependent manner. Further, neutralizing mAbs, but not control mAbs, could specifically interact with CB-119 in a dose-dependent manner. Results implicated that the second heptad repeat region of spike protein could be a good target for vaccine development against SARS-CoV.
- 中文關鍵字: --
- 英文關鍵字: heptad repeat region, monoclonal antibodies, neutralizing epitope, SARS-CoV, spike protein